Your browser is no longer supported. Please, upgrade your browser.
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own6.60% Shs Outstand90.34M Perf Week-18.03%
Market Cap1.31B Forward P/E- EPS next Y-1.57 Insider Trans41.66% Shs Float56.05M Perf Month23.20%
Income-129.10M PEG- EPS next Q-0.26 Inst Own56.80% Short Float13.67% Perf Quarter6.75%
Sales88.10M P/S14.92 EPS this Y6.30% Inst Trans13.42% Short Ratio7.12 Perf Half Y-18.30%
Book/sh1.90 P/B7.66 EPS next Y11.30% ROA-48.70% Target Price27.36 Perf Year15.94%
Cash/sh1.15 P/C12.66 EPS next 5Y- ROE-90.30% 52W Range8.82 - 21.11 Perf YTD14.66%
Dividend- P/FCF- EPS past 5Y- ROI-68.20% 52W High-31.08% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin22.60% 52W Low64.97% ATR1.18
Employees575 Current Ratio2.40 Sales Q/Q5.40% Oper. Margin- RSI (14)47.97 Volatility11.29% 8.24%
OptionableYes Debt/Eq0.37 EPS Q/Q35.30% Profit Margin- Rel Volume6.47 Prev Close16.96
ShortableYes LT Debt/Eq0.36 EarningsNov 07 BMO Payout- Avg Volume1.08M Price14.55
Recom1.70 SMA20-6.30% SMA5012.25% SMA2002.11% Volume6,959,111 Change-14.21%
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Dec-13-19 09:46AM  Athenex shares fall 19% in morning trading MarketWatch -14.21%
09:31AM  Faruqi & Faruqi, LLP is Investigating Athenex, Inc. (ATNX) on Behalf of its Shareholders PR Newswire
08:30AM  Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer GlobeNewswire
Dec-11-19 07:00AM  Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019 GlobeNewswire
Dec-09-19 08:10PM  Bytes and pieces: Extended thoughts from Armory Square Ventures leader; more news from Launch NY American City Business Journals -6.17%
Dec-05-19 08:00AM  Athenex Announces $60 Million Private Placement GlobeNewswire
Dec-02-19 05:00AM  Edited Transcript of ATNX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
Nov-21-19 08:42AM  Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock? Zacks
Nov-19-19 09:05AM  Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium GlobeNewswire +35.66%
Nov-18-19 03:29AM  Edited Transcript of ATNX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 08:35AM  Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Athenex, Inc. Announces Third Quarter 2019 Financial Results GlobeNewswire
Oct-31-19 10:34AM  Earnings Preview: Athenex (ATNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 07:00AM  Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma GlobeNewswire
Oct-28-19 03:30AM  Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment GlobeNewswire
Oct-26-19 12:33PM  Hedge Funds Have Never Been More Bullish On Athenex, Inc. (ATNX) Insider Monkey
Oct-24-19 07:00AM  Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019 GlobeNewswire
07:00AM  Athenex Provides An Update to Shareholders GlobeNewswire
Oct-21-19 04:46PM  Weekly CFO Buys Highlight GuruFocus.com -6.16%
11:29AM  Weekly CEO Buys Highlight GuruFocus.com
Oct-18-19 06:49AM  Should You Be Worried About Insider Transactions At Athenex, Inc. (NASDAQ:ATNX)? Simply Wall St. -5.28%
Oct-10-19 10:34PM  Edited Transcript of ATNX earnings conference call or presentation 7-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 12:14PM  Weekly CEO Buys Highlight GuruFocus.com
Sep-30-19 11:44AM  Weekly CEO Buys Highlight GuruFocus.com
Sep-23-19 07:00AM  Athenex to Present at the 2019 San Antonio Breast Cancer Symposium GlobeNewswire
07:00AM  Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019 GlobeNewswire
07:00AM  Athenex Completes Construction of New API Facility in Chongqing GlobeNewswire
Sep-22-19 04:44PM  Weekly CEO Buys Highlight GuruFocus.com
Sep-13-19 05:15AM  Chief scientist: David Hangauer talks about the creation of Athenex American City Business Journals
Sep-12-19 07:15AM  Is Athenex (NASDAQ:ATNX) Using Debt Sensibly? Simply Wall St.
Sep-11-19 07:00AM  Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical GlobeNewswire
Sep-04-19 07:00AM  Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy GlobeNewswire
Aug-27-19 12:00PM  7 Stocks the Insiders Are Buying on Sale InvestorPlace -6.01%
Aug-23-19 06:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $74,900 of Shares GuruFocus.com
Aug-17-19 06:40PM  Top Insider Buys Highlight for the Week of Aug. 16 GuruFocus.com
Aug-13-19 06:04AM  Analyst: Athenex drug trial results showcased 'significant commercial potential' American City Business Journals
Aug-07-19 07:23PM  Athenex, Inc. (ATNX) Q2 2019 Earnings Call Transcript Motley Fool -20.23%
04:17PM  Why This Highflying Biotech With A 50% Gain For 2019 Just Crashed Investor's Business Daily
03:46PM  Phase III results are in for Athenex's leading drug candidate, but reaction is varied American City Business Journals
07:35AM  Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:00AM  Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance GlobeNewswire
06:00AM  Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer GlobeNewswire
05:58AM  Do Insiders Own Shares In Athenex, Inc. (NASDAQ:ATNX)? Simply Wall St.
Aug-02-19 08:00AM  Athenex Provides an Update Regarding the Vasopressin Case GlobeNewswire
Jul-31-19 10:36AM  Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-29-19 08:00AM  Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019 GlobeNewswire
Jul-09-19 11:23AM  Athenex (ATNX) in Focus: Stock Moves 6.5% Higher Zacks
Jun-28-19 07:00AM  Athenex Announces Strategic Global Initiatives to Expand Clinical Operations GlobeNewswire +7.67%
Jun-27-19 08:00AM  SunGen Pharma Announces to Partner with Athenex Pharmaceutical to Launch Bivalirudin through PIV Challenges in US GlobeNewswire
Jun-24-19 07:00AM  Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase) GlobeNewswire
Jun-23-19 07:30AM  A Biotech Pro Loaded Up on These 2 Stocks Barrons.com
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
05:30PM  Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug Zacks
Jun-06-19 07:00AM  Athenex Provides an Update on its Chongqing API Plant GlobeNewswire
07:00AM  Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis GlobeNewswire
May-30-19 07:00AM  Athenex to Present at the 2019 ASCO Annual Meeting GlobeNewswire
May-09-19 03:23PM  Athenex, Inc. (ATNX) Q1 2019 Earnings Call Transcript Motley Fool
09:07AM  Athenex: 1Q Earnings Snapshot Associated Press
May-06-19 04:31PM  Why Bausch Health Companies, Aquantia, and Athenex Jumped Today Motley Fool +28.36%
10:20AM  Athenex just raised $100 million. Here's what it means American City Business Journals
08:00AM  Athenex Announces $100 Million Private Placement GlobeNewswire
May-05-19 01:44PM  Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX) Insider Monkey
May-03-19 09:12AM  Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire
Apr-25-19 07:00AM  Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire
Apr-23-19 07:00AM  Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Apr-02-19 07:00AM  Athenex Announces Appointment of John Koh as a New Board Member GlobeNewswire
Apr-01-19 01:20PM  Weekly CEO Buys Highlight GuruFocus.com
Mar-29-19 04:15PM  Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors GlobeNewswire
09:15AM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-28-19 07:00AM  Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited GlobeNewswire
Mar-27-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-26-19 07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-25-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,500 of Shares GuruFocus.com
Mar-21-19 08:30AM  Athenex Announces Xiangxue Life Sciences Receives IND Allowance from Chinas National Medical Products Administration for Cancer Immunotherapy Drug Candidate GlobeNewswire
08:30AM  Athenex Announces Expansion of Board of Directors GlobeNewswire
Mar-20-19 09:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $126,000 of Shares GuruFocus.com
Mar-19-19 08:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $226,212 of Shares GuruFocus.com
Mar-15-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $141,240 of Shares GuruFocus.com
Mar-14-19 01:29AM  Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 12:04PM  The moment Athenex executives and investors have been waiting for is almost here American City Business Journals
07:00AM  SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch GlobeNewswire
Mar-11-19 04:14PM  Athenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:10AM  Athenex: 4Q Earnings Snapshot Associated Press
07:00AM  Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-08-19 07:00AM  Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Mar-07-19 04:05AM  Athenex Regains Rights to KX2-391 in China GlobeNewswire
Mar-04-19 01:35PM  Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting PR Newswire
08:47AM  Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints MarketWatch
07:00AM  Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-25-19 07:50AM  New Research Coverage Highlights The Wendy's, Rite Aid, Invesco, LendingClub, Diodes, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
07:00AM  Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-14-19 07:00AM  Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019 GlobeNewswire
Feb-04-19 07:00AM  Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting GlobeNewswire
Jan-16-19 04:26PM  Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings Zacks
Jan-10-19 03:19PM  Athenex Completes Enrollment Target for Breast Cancer Study Zacks
05:05AM  Buffalo startups surpassed $200 million in VC and angel funding in 2018 American City Business Journals
Jan-09-19 07:00AM  Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study GlobeNewswire
Jan-04-19 03:26AM  Teresa Bair talks about the big year ahead for Athenex American City Business Journals
Jan-03-19 07:00AM  Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China GlobeNewswire -5.56%
Dec-26-18 07:00AM  Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection GlobeNewswire +15.68%
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fok MansonDirectorNov 07Buy11.6750,000583,5001,869,609Nov 12 04:06 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 22Option Exercise4.555,00022,7503,080,959Oct 23 08:03 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 21Option Exercise4.5510,00045,5003,075,959Oct 22 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 17Option Exercise4.5510,00045,5003,065,959Oct 18 04:05 PM
Sze RandollChief Financial OfficerOct 17Buy10.991,00010,9903,000Oct 17 04:11 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 17Buy10.9350,000546,50010,852,467Oct 21 06:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 16Buy10.2967,222691,71410,802,467Oct 18 06:00 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 16Buy10.166,00060,9603,055,959Oct 16 04:30 PM
Sze RandollChief Financial OfficerSep 30Buy12.621,00012,6202,000Sep 30 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 27Buy12.853,00038,5503,049,959Sep 30 04:08 PM
Kwan RudolfEVP, Chief Medical OfficerSep 25Option Exercise4.5524,000109,200132,106Sep 25 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 23Buy13.865,00069,3003,046,959Sep 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 16Buy13.5830,000407,40010,735,245Sep 18 05:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 16Buy13.575,00067,8503,041,959Sep 16 04:25 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 13Buy14.2756,416805,05610,705,245Sep 16 07:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 12Buy14.0513,584190,85510,648,829Sep 16 07:31 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 23Buy14.985,00074,9003,036,959Aug 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 16Buy14.9620,000299,20010,635,245Aug 16 05:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 15Buy15.0030,000450,00010,615,245Aug 16 05:31 PM
Kwan RudolfEVP, Chief Medical OfficerAug 15Buy14.851,00014,850108,106Aug 16 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 15Buy14.9010,000149,0003,031,959Aug 15 04:14 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 08Buy15.7630,000472,80010,585,245Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 07Buy14.43733,12710,576,25110,555,245Aug 09 05:55 PM
Davis Stephanie ADirectorJun 26Buy18.0010,000180,00010,000Jun 27 08:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 25Buy17.891,49526,7469,822,118Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 24Buy17.9020,786372,0699,820,623Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 21Buy17.8523,073411,8539,799,837Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 18Buy17.7350,742899,6569,776,764Jun 20 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 17Buy17.94130,0002,332,2009,726,022Jun 19 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 14Buy17.69324,2905,736,6909,596,022Jun 18 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 13Buy17.0575,7101,290,8569,271,732Jun 17 08:00 PM
Kanfer JordanDirectorJun 06Buy15.012,50037,5254,184Jun 07 04:16 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 06Buy12.71100,0001,271,1489,196,022May 08 05:04 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardApr 24Option Exercise4.5510,00045,5003,021,959Apr 25 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 28Buy12.4010,000124,0002,996,385Mar 28 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy12.4010,000124,0002,986,385Mar 27 04:23 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 25Buy12.4510,000124,5002,976,385Mar 25 04:08 PM
Zuo William WeiPresident, China DivisionMar 25Buy12.471,00012,4701,118,777Mar 26 04:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 21Buy12.571,00012,5702,966,385Mar 21 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy12.0010,500126,0002,965,385Mar 20 04:38 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy12.1318,649226,2122,954,885Mar 19 05:03 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy12.524,00050,0802,936,236Mar 18 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 15Buy11.7712,000141,2402,932,236Mar 15 05:08 PM
Trainor-Degirolamo SheldonDirectorMar 15Sale11.7754,079636,510611,333Mar 18 04:21 PM
Trainor-Degirolamo SheldonDirectorMar 14Sale11.79671665,412Mar 18 04:21 PM
Zhang Song-YiDirectorMar 13Sale11.824,43252,3863,938,613Mar 14 04:15 PM
Trainor-Degirolamo SheldonDirectorMar 13Sale11.7745,915540,420665,418Mar 14 04:11 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy11.802,81433,2052,920,236Mar 12 04:55 PM
Zhang Song-YiDirectorMar 12Sale11.8983,381991,4003,943,045Mar 14 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 11Buy11.7810,000117,8002,917,422Mar 11 04:53 PM
Zhang Song-YiDirectorMar 11Sale11.8532,240382,0444,026,426Mar 14 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 20Option Exercise4.5510,00045,5002,907,422Dec 20 05:26 PM